Ltr Pharma Limited · ASX:LTP
Ltr Pharma — Shareholder Meeting (November 2024)
13 slides from Ltr Pharma's shareholder meeting presentation, Nov 27, 2024
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 27 November 2024
Slide 2: A transformative year of clinical and commercial success
A transformative year of clinical and commercial success Australian Financial Year For personal use only Q2 2023/24 Q3 2023/24 Q4 2023/24 Q1 2024/25 Q2 2024/25 ASX listing Manufacturing Positive clinical Global partnership Final clinical study validation study results with Aptar Pharma results confi
Slide 3: Investment Highlights
Investment Highlights LTR Pharma positioned in a clear gap in the market For personal use only Expedited Compelling pivotal Blockbuster Blue chip Multiple upcoming path to market pharmacokinetic market with issues partners milestones study data Repurposed drugs with novel 470% faster absorption than
Slide 4: Understanding the Market Need
Understanding Psychological Impact Physical causes the Market Need ‣ Heart Health ‣ Relationship problems ‣ Mental Wellbeing A significant healthcare ‣ Hormone Balance For personal use only ‣ Day to day stress challenge affecting ‣ Metabolic Health relationships and ‣ Medical Treatments quality of l
Slide 5: Global Market Need
Global Market Need ED can impact physical and psychological health Global ~322m men by 2025 For personal use only USA China Aus EU 60.7% ~30m ~33m ~150m of males 45y/o+ Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023 AGM 2024 5
Slide 6: Estimated Market size
Estimated Market size Forecast to be US$6.0B market by 2028 $5.94B For personal use only US$6.0B US$5.0B 7.0% CAGR US$4.0B $3.68B $4.15B $3.87B US$ billions $3.61B US$3.0B $3.38B $3.16B $2.95B $2.76B $2.58B US$2.0B US$1.0B $1.56B $1.67B $1.79B $1.18B $1.27B $1.36B $1.45B $1.11B US$0.0B 2021 2022 202
Slide 7: Current treatments
Current treatments Gold standard are PDE5 inhibitor tablets which have several drawbacks For personal use only Phosphodiesterase-5 (PDE5) inhibitors are first-line treatments Issues with PDE5 inhibitor tablets Main Time before sexual Approval Generic Does not work Product Brand(s) activity for dose
Slide 8: SPONTAN® The Fast-Acting Solution
SPONTAN® The Fast-Acting Solution Transforming ED treatment with speed and confidence For personal use only Speed Matters Healthcare Professional Insight Peak concentration in as little as 9 mins, 470% faster than oral tablets Patients can respond in as little as 5 minutes, Average onset: 12 mins vs
Slide 9: Making headlines – all eyes on LTP
Making headlines – all eyes on LTP LTR Pharma engaged For personal use only positively with all tiers of the media in FY24, including quality, regular coverage in industry, business, health and top tier mediums. Whilst a high volume of headlines focused on the Company’s outstanding share price growt
Slide 10: Company History
Company History Progressed company substantially derisking the proposition For personal use only 2020 - 2021 Acquired exclusive worldwide rights to Establishment of the Validated the US FDA’s 505(b)(2) develop, manufacture and market SPONTAN® Scientific Advisory Board regulatory pathway through an t
Slide 11: Board of Directors
Board of Directors Seasoned leadership driving innovation and growth in healthcare For personal use only LEE RODNE MS MA JA MCGUIRE DR JULIAN CHICK (Executive Chairman) (Independent Non-Executive Director) (Independent Non-Executive Director) ▲ 25 years in healthcare and tech ▲ 15 years of experienc
Slide 12: Global Team, Strategic US Presence
Global Team, Strategic US Presence Experienced leadership across key markets For personal use only Executive Chairman | Lee Rodne General Manager & Business Development US |Tom Riester 25 years in healthcare and tech sectors in both public ASX and private enterprises. 25 years experience in sales an
Slide 13: Upcoming Milestones
Upcoming Milestones Multiple value inflection points in the year ahead For personal use only Expanding Manufacturing Online Regulatory Potential product portfolio scale up prescribing studies partnerships & & meetings licensing AGM 2024 13